+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Future of Bullous Pemphigoid R&D Pipeline Drugs and Companies- Analysis of Global Bullous Pemphigoid Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4745217
  • Report
  • January 2019
  • Region: Global
  • 60 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Bioverativ Inc
  • Eli Lilly and Co
  • iCo Therapeutics Inc
  • Immungenetics AG
  • TWi Biotechnology Inc
  • MORE
The global demand for Bullous Pemphigoid treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Bullous Pemphigoid pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Bullous Pemphigoid pipeline companies from advancing their products into Phase 3 or Phase 4.

Bullous Pemphigoid Report Description

The H1- 2019 pipeline review report on Bullous Pemphigoid pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Bullous Pemphigoid pipeline compounds.

The Bullous Pemphigoid pipeline guide presents information on all active drugs currently being developed for Bullous Pemphigoid. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Bullous Pemphigoid pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Bullous Pemphigoid drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Bullous Pemphigoid product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Bullous Pemphigoid pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Bullous Pemphigoid pipeline report includes
  • An overview of Bullous Pemphigoid disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of pipeline compounds
  • Company wise list of pipeline compounds
  • Mechanism of Action wise pipeline compounds
For each pipeline product, the following details are provided
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Bullous Pemphigoid pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Bullous Pemphigoid pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into the market through in-depth strategic analysis review
  • Know the list of companies participating in global Bullous Pemphigoid pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Bioverativ Inc
  • Eli Lilly and Co
  • iCo Therapeutics Inc
  • Immungenetics AG
  • TWi Biotechnology Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Bullous Pemphigoid Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology

3. Executive Summary
3.1 Bullous Pemphigoid Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Bullous Pemphigoid pipeline, H1- 2019
3.5 Mechanism of Action wise Bullous Pemphigoid Pipeline Candidates

4. Akari Therapeutics Plc Bullous Pemphigoid Pipeline Details
4.1 Akari Therapeutics Plc Business Profile
4.2 Akari Therapeutics Plc Bullous Pemphigoid Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5. Bioverativ Inc Bullous Pemphigoid Pipeline Details
5.1 Bioverativ Inc Business Profile
5.2 Bioverativ Inc Bullous Pemphigoid Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6. Eli Lilly and Co Bullous Pemphigoid Pipeline Details
6.1 Eli Lilly and Co Business Profile
6.2 Eli Lilly and Co Bullous Pemphigoid Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7. iCo Therapeutics Inc Bullous Pemphigoid Pipeline Details
7.1 iCo Therapeutics Inc Business Profile
7.2 iCo Therapeutics Inc Bullous Pemphigoid Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8. Immungenetics AG Bullous Pemphigoid Pipeline Details
8.1 Immungenetics AG Business Profile
8.2 Immungenetics AG Bullous Pemphigoid Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9. TWi Biotechnology Inc Bullous Pemphigoid Pipeline Details
9.1 TWi Biotechnology Inc Business Profile
9.2 TWi Biotechnology Inc Bullous Pemphigoid Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10. TxCell SA Bullous Pemphigoid Pipeline Details
10.1 TxCell SA Business Profile
10.2 TxCell SA Bullous Pemphigoid Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11. Latest Bullous Pemphigoid Drug Pipeline Developments, 2019

12. Appendix
12.1 About Us
12.2 Sources and Methodology
12.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Akari Therapeutics Plc
  • Bioverativ Inc
  • Eli Lilly and Co
  • iCo Therapeutics Inc
  • Immungenetics AG
  • TWi Biotechnology Inc
  • TxCell SA
Note: Product cover images may vary from those shown
Adroll
adroll